“If you look at the tubeless market, you know, we're seeing growth rates in excess of 25% annually,” Tandem Diabetes CEO John Sheridan explains to Bloomberg Intelligence about the growth opportunities in insulin pumps. In this episode of Vanguards of Health Care, Sheridan sits down with BI analyst Matt Henriksson for an in-depth interview about Tandem’s pending launch of Mobi Tubless, an insulin pump designed to wear on the body for discretion and the AI-powered Control-IQ Plus algorithm for simplicity. The conversation also touches on the company’s pay-as-you-go business model and future product development, including the next generation Mobi pumps utilizing Sigi technology from its AMF acquisition and a new closed loop algorithm.

See omnystudio.com/listener for privacy information.

“It’s not about the technology itself, it’s about the form factor,” says Dr. Toyin Ajayi, co-founder and CEO of Cityblock Health. She joins Bloomberg Intelligence analyst Jonathan Palmer to explain how the company is redesigning care for complex Medicaid and Medicare populations around medical, behavioral and social needs. Ajayi details Cityblock’s value-based model, which rewards better outcomes and lower costs, and explains how AI is increasingly shaping care. One surprising finding: seniors and Medicaid members are willing to engage with technology when it comes through familiar channels like voice and text. The conversation also explores Cityblock’s use of real-world data to guide next-best actions and its ambition to expand nationally.

See omnystudio.com/listener for privacy information.

“Clinical data is the key to being successful in diagnostics,” Steve Chapman, CEO of Natera, tells Bloomberg Intelligence analyst Jonathan Palmer as he explains how an early bet on evidence helped turn a small genetic-testing company into a broad diagnostics platform. Chapman traces Signatera from a side project into a leading minimal residual disease (MRD) test and details Natera’s nearly $1 billion R&D investment to push into genome-based testing, early cancer detection and new indications. The conversation also explores the next layer of value from Natera’s platform — millions of longitudinal data points, AI-enhanced test results and patient experiences, more efficient biopharma trials and the potential to use neoantigen prediction algorithms to support personalized cancer vaccines.

See omnystudio.com/listener for privacy information.